PRUNE Antibody

What is PRUNE and why is it a significant research target?

PRUNE (also known as PRUNE1) is a phosphodiesterase with higher activity toward cAMP than cGMP as substrate. This protein plays critical roles in multiple cellular processes including cell proliferation, migration, and differentiation. It functions as a negative regulator of NME1 and is involved in the regulation of neurogenesis and microtubule polymerization . PRUNE is particularly significant in neurodevelopment research because it is crucial for normal brain development, with mutations associated with microcephaly and neurodevelopmental impairment . These multiple functions make PRUNE an important research target for both basic cell biology and clinical neurodevelopmental research.

What types of PRUNE antibodies are available for research applications?

Currently, researchers have access to multiple types of PRUNE antibodies that vary in host organism and production methods:

When selecting a PRUNE antibody, researchers should consider their specific application requirements and target species. Unlike many commercial antibodies that lack proper characterization, these PRUNE antibodies have been validated in multiple applications with appropriate controls .

What are the recommended dilutions for PRUNE antibody in different applications?

Optimal dilutions for PRUNE antibody vary by application type and specific antibody:

These recommended dilutions should serve as starting points. Researchers should perform titration experiments to determine optimal concentrations for their specific experimental conditions and sample types.

How should I design proper controls when using PRUNE antibody in my experiments?

Proper controls are essential for validating PRUNE antibody specificity and experimental results. Recent research has highlighted that knockout (KO) cell lines provide superior controls compared to other approaches, particularly for Western blots and immunofluorescence imaging . When designing experiments with PRUNE antibody, implement the following control strategy:

• Positive controls: Include samples known to express PRUNE (e.g., HeLa cells or HepG2 cells for human PRUNE)

• Negative controls:

  • Primary antibody omission control

  • Isotype control (using matched IgG instead of primary antibody)

  • Ideally, PRUNE knockout cells when available

• Peptide competition: Pre-incubation of antibody with immunizing peptide to confirm specificity

• Loading controls: For Western blot, include housekeeping proteins (β-actin, GAPDH)

Research has demonstrated that approximately 12 publications per protein target include data from antibodies that fail to recognize the relevant target protein , highlighting the critical importance of rigorous controls in antibody-based experiments.

What sample preparation methods are critical for PRUNE antibody staining in tissue sections?

Sample preparation is crucial for successful PRUNE antibody staining in tissue sections. For optimal results with PRUNE antibody in immunohistochemistry applications:

• Fixation: Use 10% neutral-buffered formalin (NBF) at room temperature for 16-32 hours. Overfixation or underfixation can significantly impact antibody accessibility and epitope preservation .

• Antigen retrieval: Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) under high pressure . This step is critical as it unmasks epitopes that may be cross-linked during fixation.

• Blocking: Block with 10% normal goat serum for 30 minutes at room temperature to reduce background staining .

• Primary antibody incubation: Incubate with primary antibody (in 1% BSA) at 4°C overnight for optimal binding .

• Detection: Use biotinylated secondary antibody and visualize using an HRP-conjugated SP system for sensitive detection of PRUNE .

If initial staining results are suboptimal, consider optimizing the antigen retrieval conditions based on your specific tissue type and fixation parameters .

How can I determine if my PRUNE antibody is detecting the correct target?

With approximately 50% of commercial antibodies failing to meet basic characterization standards , validating that your PRUNE antibody is detecting the correct target is essential. Implement these methodological approaches:

• Recombinant expression systems: Compare PRUNE-transfected cells with non-transfected controls. A specific PRUNE antibody should show significantly stronger signal in transfected cells, as demonstrated with ab88613 .

• RNA interference: Perform siRNA or shRNA knockdown of PRUNE and confirm reduced antibody signal correlates with reduced PRUNE expression.

• Knockout validation: The gold standard for antibody validation is testing in knockout models. Recent studies confirm knockout cell lines are superior to other controls, especially for Western blot and immunofluorescence applications .

• Molecular weight verification: Confirm that the observed band appears at the expected molecular weight (approximately 60 kDa for PRUNE despite the predicted 50 kDa size) .

• Multi-technique validation: Verify target detection across multiple techniques (e.g., if the antibody works in both Western blot and immunofluorescence).

What are common issues encountered with PRUNE antibody in Western blot applications and how can they be resolved?

When using PRUNE antibody in Western blot applications, researchers may encounter several challenges that can be systematically addressed:

When troubleshooting Western blots with PRUNE antibody, a methodical approach starting with verified positive controls (such as PRUNE-transfected 293T cells) will help identify the specific issue in your experimental system .

How should I optimize immunostaining protocols for PRUNE detection in different cell types?

Optimizing immunostaining protocols for PRUNE detection requires systematic adjustment of multiple parameters based on the specific cell type being examined:

• Fixation optimization:

  • For adherent cells: Test both 4% paraformaldehyde (10-15 minutes) and methanol (-20°C, 5 minutes)

  • For suspension cells: Use 2% paraformaldehyde with permeabilization

• Permeabilization options:

  • For cytoplasmic PRUNE: 0.1-0.5% Triton X-100 (5-10 minutes)

  • For membrane-associated PRUNE: 0.1-0.2% saponin (gentler permeabilization)

• Antibody concentration titration:

  • Start with recommended dilution (10 μg/ml for ab88613)

  • Test serial dilutions to optimize signal-to-background ratio

• Incubation conditions:

  • Temperature: Compare room temperature (1-2 hours) vs. 4°C (overnight)

  • Diluent composition: Test different BSA percentages (1-3%)

• Signal amplification methods:

  • For low expression: Consider tyramide signal amplification

  • For co-localization studies: Use directly conjugated secondary antibodies

Always include appropriate controls with each optimization experiment and maintain consistent parameters between experimental groups to ensure valid comparisons.

What are the key differences between polyclonal and monoclonal PRUNE antibodies, and how should this influence my selection?

Understanding the differences between polyclonal and monoclonal PRUNE antibodies is crucial for selecting the appropriate reagent for your research applications:

Recent research indicates that recombinant antibodies generally outperform both traditional monoclonal and polyclonal antibodies across multiple assays . When selecting between currently available PRUNE antibodies, consider:

• Mouse polyclonal antibody (ab88613) for Western blot and immunofluorescence applications requiring detection of full-length PRUNE

• Rabbit polyclonal antibody (ab237518) for applications requiring detection of the N-terminal region (aa 1-200) of PRUNE, particularly in immunohistochemistry

How can I use PRUNE antibody in flow cytometry for studying neuronal differentiation models?

Flow cytometry with PRUNE antibody can provide valuable insights into neuronal differentiation, given PRUNE's role in neurogenesis and brain development . To effectively implement this approach:

• Sample preparation optimization:

  • Single-cell suspensions must be prepared with minimal damage to surface epitopes

  • For adherent neuronal cultures, use gentle enzymatic dissociation (Accutase preferred over trypsin)

  • Include dead cell discrimination dye (e.g., 7-AAD or DAPI)

• Staining protocol development:

  • Fixed and permeabilized cells required (PRUNE is intracellular)

  • Sequential staining recommended for multi-parameter analysis

  • Compensation controls essential if using multiple fluorophores

• Gating strategy design:

  • Exclude debris and doublets

  • Gate on live cells using viability dye

  • For neuronal differentiation, consider co-staining with neuronal markers (β-III-tubulin, MAP2)

• Controls and validation:

  • FMO (fluorescence minus one) controls for accurate gating

  • Isotype controls to assess background

  • Blocking peptide competition to confirm specificity

  • PRUNE knockdown cells as biological negative controls

When analyzing data, quantify both the percentage of PRUNE-positive cells and the mean fluorescence intensity (MFI) to assess changes in expression levels during differentiation stages .

What approaches can be used to study PRUNE interactions with NME1 and their role in microtubule dynamics?

PRUNE functions as a negative regulator of NME1 and is involved in the regulation of microtubule polymerization . To investigate these interactions:

• Co-immunoprecipitation (Co-IP) approaches:

  • Perform reciprocal Co-IPs using both PRUNE and NME1 antibodies

  • Use native lysis conditions to preserve protein-protein interactions

  • Include appropriate negative controls (IgG, lysates from cells lacking one interaction partner)

  • Western blot analysis with specific antibodies for each protein partner

• Proximity ligation assay (PLA):

  • Allows visualization of protein interactions (<40 nm proximity) in situ

  • Requires validated antibodies from different host species

  • Provides spatial information about interaction sites within cells

  • Quantifiable using image analysis software

• Live-cell imaging of microtubule dynamics:

  • Transfect cells with fluorescently tagged tubulin constructs

  • Manipulate PRUNE levels (overexpression or knockdown)

  • Track parameters: polymerization rate, catastrophe frequency, rescue frequency

  • Correlate with PRUNE expression/localization using immunofluorescence

• In vitro microtubule polymerization assays:

  • Purify PRUNE protein (using antibody-based affinity purification)

  • Assess direct effects on tubulin polymerization using turbidity assays

  • Measure the impact of NME1 addition on PRUNE-mediated effects

These approaches provide complementary data to understand how PRUNE regulates microtubule dynamics, potentially through its interaction with NME1 and other partners.

How can PRUNE antibody be used to investigate pathological mechanisms in neurodevelopmental disorders?

Given PRUNE's critical role in brain development and its association with microcephaly and neurodevelopmental impairment , PRUNE antibody can be a valuable tool for investigating disease mechanisms:

• Immunohistochemical analysis of patient-derived tissues:

  • Compare PRUNE expression and localization in post-mortem brain tissues from patients vs. controls

  • Use rabbit polyclonal antibody (ab237518) optimized for IHC-P applications

  • Implement standardized antigen retrieval with citrate buffer (pH 6.0)

  • Quantify expression in specific brain regions and cell types

• Patient-derived cell models:

  • Analyze PRUNE expression in fibroblasts or induced pluripotent stem cells (iPSCs) from patients with PRUNE mutations

  • Differentiate iPSCs into neural progenitors and mature neurons

  • Track PRUNE expression during differentiation using Western blot and immunofluorescence

  • Correlate with cellular phenotypes (proliferation, migration, neurite outgrowth)

• Functional rescue experiments:

  • Express wild-type vs. mutant PRUNE in cellular models

  • Use PRUNE antibody to confirm expression levels

  • Assess restoration of normal cellular phenotypes

  • Investigate downstream signaling pathways affected by mutations

• Co-localization studies:

  • Examine PRUNE localization relative to cytoskeletal components and developmental markers

  • Perform high-resolution microscopy (confocal or super-resolution)

  • Quantify co-localization coefficients in different cellular compartments

These approaches can provide insights into how PRUNE mutations contribute to neurodevelopmental disorders and identify potential therapeutic targets.

How can I verify the reproducibility of my PRUNE antibody across different experimental batches?

Ensuring reproducibility with PRUNE antibody requires systematic quality control measures across experimental batches:

• Establish validation benchmarks:

  • Create standardized positive control lysates/samples

  • Document expected staining patterns and band intensities

  • Maintain digital images of reference experiments

• Implement antibody validation protocols:

  • Aliquot antibodies upon receipt to minimize freeze-thaw cycles

  • Test each new lot against reference standards

  • Maintain consistent storage conditions (-20°C, avoid repeated freeze-thaw)

• Develop quantitative metrics:

  • For Western blots: Signal-to-noise ratio, band intensity relative to loading control

  • For IF/IHC: Staining intensity scores, background levels

  • For flow cytometry: Mean fluorescence intensity, percent positive population

• Control for experimental variables:

  • Document and standardize sample preparation methods

  • Maintain consistent antibody dilutions across experiments

  • Use the same secondary antibody lots when possible

• Statistical validation:

  • Perform technical replicates (minimum n=3)

  • Calculate coefficients of variation between experiments

  • Define acceptable thresholds for variation

Recent research has highlighted that approximately 50% of commercial antibodies fail to meet basic characterization standards , underscoring the importance of rigorous validation. By implementing these measures, researchers can ensure that observed experimental differences reflect true biological variation rather than technical artifacts.

What documentation should I maintain about PRUNE antibody validation for publication purposes?

With increasing journal requirements for antibody validation, maintaining comprehensive documentation is essential for publication and reproducibility:

• Antibody identification information:

  • Commercial supplier and catalog number (e.g., ab88613, ab237518)

  • Clone name/number (for monoclonals) or host species and immunogen (for polyclonals)

  • Lot number (particularly important for polyclonal antibodies)

  • RRID (Research Resource Identifier) when available

• Validation experiments performed:

  • Western blot showing single band of expected size (approximately 60 kDa for PRUNE)

  • Positive control samples (PRUNE-transfected cells, tissues known to express PRUNE)

  • Negative controls (non-transfected cells, PRUNE knockout cells if available)

  • Reduction/absence of signal with blocking peptide

• Application-specific optimization:

  • Dilution series tested and optimal concentration determined

  • Sample preparation methods (lysis buffers, fixation conditions)

  • Antigen retrieval methods for IHC (high pressure in citrate buffer pH 6.0)

  • Blocking conditions (10% normal goat serum, 30 min at RT)

• Supporting images:

  • Full unedited blot images including molecular weight markers

  • Representative images of positive and negative controls

  • Raw data from quantitative analyses

Journals increasingly require this level of documentation to address the "antibody characterization crisis" that has led to an estimated financial loss of $0.4–1.8 billion per year in the United States alone due to poorly characterized antibodies .